Jeremy Bender
Director Ejecutivo en DAY ONE BIOPHARMACEUTICALS, INC. .
Fortuna: 22 M $ al 30/04/2024
Relaciones activas
| Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
|---|---|---|---|---|
| Charles York | M | 47 |
DOT Therapeutics-2, Inc.
 DOT Therapeutics-2, Inc. Pharmaceuticals: MajorHealth Technology DOT Therapeutics-2, Inc. develops new therapies that change the outcome for people of all ages living with cancer. The company was founded by Julie Grant and Samuel Blackman and is headquartered in South San Francisco, CA. | 3 años |
| Samuel Blackman | M | 55 |
DOT Therapeutics-2, Inc.
DOT Therapeutics-2, Inc. Pharmaceuticals: MajorHealth Technology DOT Therapeutics-2, Inc. develops new therapies that change the outcome for people of all ages living with cancer. The company was founded by Julie Grant and Samuel Blackman and is headquartered in South San Francisco, CA. | 6 años |
| Pablo Cagnoni | M | 60 |
Allos Therapeutics, Inc.
 Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 8 años |
| Charles Sermon | M | 55 | 9 años | |
| Dan Becker | M | 49 |
DOT Therapeutics-2, Inc.
DOT Therapeutics-2, Inc. Pharmaceuticals: MajorHealth Technology DOT Therapeutics-2, Inc. develops new therapies that change the outcome for people of all ages living with cancer. The company was founded by Julie Grant and Samuel Blackman and is headquartered in South San Francisco, CA. | 5 años |
| John Valliant | M | 54 | 10 años | |
| Sona Saira Ramasastry | F | 48 |
DOT Therapeutics-2, Inc.
DOT Therapeutics-2, Inc. Pharmaceuticals: MajorHealth Technology DOT Therapeutics-2, Inc. develops new therapies that change the outcome for people of all ages living with cancer. The company was founded by Julie Grant and Samuel Blackman and is headquartered in South San Francisco, CA. | 3 años |
| Natalie Holles | F | 51 |
DOT Therapeutics-2, Inc.
DOT Therapeutics-2, Inc. Pharmaceuticals: MajorHealth Technology DOT Therapeutics-2, Inc. develops new therapies that change the outcome for people of all ages living with cancer. The company was founded by Julie Grant and Samuel Blackman and is headquartered in South San Francisco, CA. | 3 años |
| Denise Scots-Knight | M | 64 | 9 años | |
| Michael Gladstone | M | 37 |
DOT Therapeutics-2, Inc.
DOT Therapeutics-2, Inc. Pharmaceuticals: MajorHealth Technology DOT Therapeutics-2, Inc. develops new therapies that change the outcome for people of all ages living with cancer. The company was founded by Julie Grant and Samuel Blackman and is headquartered in South San Francisco, CA. | 5 años |
| Michael Wyzga | M | 69 | 5 años | |
| Deepa Pakianathan | M | 59 | 5 años | |
| Daniel O'Day | M | 59 | 5 años | |
| Barbara Duncan | F | 59 | 4 años | |
| Raphaël Rousseau | M | 55 | 1 años | |
| J. Garland | M | 55 | 3 años | |
| Garry Nicholson | M | 69 | 2 años | |
| Donald Bergstrom | M | 52 | 3 años | |
| Edward Albini | M | 66 | 11 años | |
| Sandra Horning | M | 75 | 4 años | |
| Jeffrey R. Latts | M | 76 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 17 años |
| Amanda Cray | F | - | - | |
| John Freund | M | 70 | 10 años | |
| Philina Lee | M | 47 | 3 años | |
| Steven Gannon | M | 62 | 4 años | |
| John P. Richard | M | 66 | 9 años | |
| John Josey | M | 63 | 4 años | |
| Harish M. Manwani | M | 70 | 6 años | |
| Javier Rodriguez | M | 53 | 4 años | |
| Anders Olof Adolf Ekblom | M | 70 | 9 años | |
| Mohit Rawat | M | - | 3 años | |
| Daniel Shames | M | - | 2 años | |
| Johanna Mercier | F | 54 | 5 años | |
| Dmitri Bobilev | M | - | 2 años | |
| Joydeep Ganguly | M | - | 5 años | |
| Richard Francis | M | - | 5 años | |
| Lauren Merendino | F | 49 | 1 años | |
| Jaa Roberson | F | - | 3 años | |
| Mike Pregih | M | - | - | |
| Suba Krishnan | M | 59 | 4 años | |
| Laura Cooper | F | - | 2 años | |
| Christine Fox | F | 43 | 3 años | |
| Cara Ferreira | M | - | 4 años | |
| Adam Dubow | M | 57 | 2 años | |
| John Crowley | M | 51 | 5 años | |
| Janet Dorling | F | 50 | 4 años | |
| Eric Burak | M | - | 7 años | |
| Christopher Leamon | M | 57 | 3 años | |
| Eric S. Hoffman | M | 54 | 3 años | |
| John Lewicki | M | 72 | 4 años | |
| Pierre Jacquet | M | 57 | 3 años | |
| Justin Roberts | M | - | 2 años | |
| Maria D. Stahl | F | 53 | 4 años | |
| Michael E. Schick | M | 57 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 15 años |
| Teresa Bitetti | F | - | 1 años | |
| Merdad Parsey | M | 61 | 5 años | |
| Annalisa Jenkins | M | 58 | 2 años | |
| Wills Hughes-Wilson | F | 53 | 6 años | |
| Marc J. Yoskowitz | M | - | 2 años | |
| David Meek | M | 59 | 1 años | |
| William Grossman | M | 54 | - | |
| Habib Dable | M | 54 | - | |
| Davy Chiodin | M | - | - |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
| Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
|---|---|---|---|---|
| Gregg Alton | M | 58 | 20 años | |
| Julie Grant | F | 41 | 5 años | |
| John Milligan | M | 63 | 28 años | |
| Stephen J. Hoffman | M | 70 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 18 años |
| Michael E. Hart | M | - |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 5 años |
| Paul Berns | M | 57 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 6 años |
| Alastair MacKinnon | M | 53 | 7 años | |
| Peter John Fellner | M | 80 | 7 años | |
| Robin Washington | F | 60 | 11 años | |
| Shelly Pinto | F | 48 |
Tizona Therapeutics, Inc.
 Tizona Therapeutics, Inc. BiotechnologyHealth Technology Tizona Therapeutics, Inc. is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Its products include anti-ccr4 antibody for the treatment of cancer, il-35 antagonists for the treatment of cancer, and il-35 agonists for the treatment of autoimmune diseases. The company was founded by Charles G. Drake, Vijay K. Kuchroo, Drew M. Pardoll, Dario Vignali, Wayne A. Marasco and Jedd D. Wolchok and is headquartered in South San Francisco, CA. | 5 años |
| Derek DiRocco | M | 43 | - | |
| John McHutchison | M | 66 | 9 años | |
| Peter Bains | M | 65 | 6 años | |
| Andrew Cheng | M | 57 | 19 años | |
| Paul Blackburn | M | - | 5 años | |
| Anne Philomena Hyland | F | 64 | - | |
| Nishan de Silva | M | 51 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 1 años |
| Cecilia Gonzalo | F | 49 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 1 años |
| Kunal Ashok Kashyap | M | 59 | 6 años | |
| Chau Khuong | M | 48 | 4 años | |
| Heather Elizabeth Preston | M | 58 | 4 años | |
| David Stout | M | 69 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 3 años |
| Timothy Patrick Lynch | M | 54 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 6 años |
| Joseph Turner | M | 72 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | - |
| Norbert W. Bischofberger | M | 68 | 28 años | |
| Johan Rutger Christenson | M | 65 | 6 años | |
| John Martin | M | 72 | 29 años | |
| Monica Viziano | M | 57 | 18 años | |
| Christopher Freeman | M | 50 | 1 años | |
| Adrian Ray | M | 48 | 2 años | |
| Martin J. Silverstein | M | 69 | 2 años | |
| Kenneth F. Boehm | M | - | 11 años | |
| Martín Sebastian Olivo | M | 48 | 3 años | |
| Lian Hong Xu | M | 58 | 20 años | |
| Sung Lee | M | 53 | 14 años | |
| Aaron Brinkworth | M | - | 22 años |
Estadísticas
| País | Relaciones | % del total |
|---|---|---|
| Estados Unidos | 58 | 58.59% |
| Reino Unido | 22 | 22.22% |
| Canadá | 20 | 20.20% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Jeremy Bender
- Red Personal
